NUVB Stock Risk & Deep Value Analysis
Nuvation Bio Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About NUVB Stock
We analyzed Nuvation Bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NUVB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is NUVB Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Low
What Are the Red Flags for NUVB?
- ⚠
Disappointing taletrectinib commercial uptake or sales trajectory.
- ⚠
Negative clinical trial results for pipeline assets (NUV-868, NUV-520).
- ⚠
Increased competition from next-generation ROS1 inhibitors.
- ⚠
Need for significant equity financing resulting in substantial dilution.
Unlock NUVB Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Nuvation Bio Inc (NUVB) Do?
Market Cap
$3.22B
Sector
Healthcare
Industry
Biotechnology
Employees
291
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Visit Nuvation Bio Inc WebsiteIs NUVB Stock Undervalued?
Unlock the full AI analysis for NUVB
Get the complete DVR score, risk analysis, and more
Does NUVB Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property protection and the differentiated clinical profile of its lead asset, taletrectinib. Its durability depends on successful pipeline development to create new revenue streams before patent cliffs become a significant issue and the ability to fend off emerging competitive therapies. The experienced leadership also provides an operational advantage.
Moat Erosion Risks
- •Patent expiration and generic competition for taletrectinib in the long term.
- •Development of superior next-generation ROS1 inhibitors by competitors.
- •Clinical trial failures for pipeline assets, limiting future growth opportunities.
NUVB Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive NUVB Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Late March/Early April 2026) – Focus on initial taletrectinib sales figures and guidance.
- •Q1 2026 Earnings Report (Estimated Early May 2026) – Further insights into taletrectinib commercial traction and ramp-up.
Medium-Term (6-18 months)
- •Updates on NUV-868 (PARP inhibitor) clinical progression (IND clearance, Phase 1 initiation/early data).
- •Potential ex-U.S. partnership announcements for taletrectinib commercialization.
- •Updates on NUV-520 (BET inhibitor) preclinical/IND-enabling studies.
Long-Term (18+ months)
- •Taletrectinib label expansion into other ROS1-fusion positive cancers or earlier lines of therapy.
- •Multiple pipeline assets (e.g., NUV-868, NUV-520) advancing into pivotal clinical trials.
- •Potential for NUVB to become an acquisition target for a larger pharmaceutical company seeking precision oncology assets.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for NUVB?
- ✓
Acceleration in taletrectinib revenue growth and market penetration rates.
- ✓
Positive clinical trial readouts for NUV-868 or NUV-520.
- ✓
Successful management of cash burn and extended cash runway without excessive dilution.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NUVB (Nuvation Bio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
